ONO PHARMACEUTICAL CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: $7.1B

Website: https://www.ono.co.jp/

Clinical Trials

Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study

Not yet recruiting

Conditions: Primary Central Nervous System Lymphoma (PCNSL)

First Posted Date: 2024-12-03

Last Posted Date: 2024-12-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 35

Registration Number: NCT06714370

A Study of ONO-1110 in Patients With Postherpetic Neuralgia

Phase 2

Not yet recruiting

Conditions: Postherpetic Neuralgia (PHN)

Interventions: Drug: ONO-1110
Drug: Placebo

First Posted Date: 2024-11-27

Last Posted Date: 2024-11-27

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 140

Registration Number: NCT06708416

ONO-4059 Study in Patients With Steroid-resistant Pemphigus

Phase 3

Recruiting

Conditions: Pemphigus
Steroid-resistant Pemphigus

Interventions: Drug: ONO-4059
Drug: ONO-4059 placebo

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-20

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 34

Registration Number: NCT06696716

Locations: 🇯🇵
Ichinomiya Municipal Hospital, Aichi, Japan
🇯🇵
Nagoya City University Hospital, Aichi, Japan
🇯🇵
Kurume University Hospital, Fukuoka, Japan

and more 17 locations

Study to ONO-4538 in Patients With Rhabdoid Tumor

Phase 2

Recruiting

Conditions: Rhabdoid Tumor

Interventions: Drug: ONO-4538

First Posted Date: 2024-10-02

Last Posted Date: 2024-12-02

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 23

Registration Number: NCT06622941

Locations: 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵
Osaka City General Hospital, Osaka, Japan

A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: ONO-7018

First Posted Date: 2024-10-02

Last Posted Date: 2024-11-21

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 24

Registration Number: NCT06622226

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya-shi, Aichi, Japan
🇯🇵
National Hospital Organization Shibukawa Medical Center, Shibukawa-shi, Gumma, Japan
🇯🇵
Hiroshima Red Cross Hospital Atomic-bomb Survivors Hospital, Hiroshima-shi, Hiroshima, Japan

and more 3 locations

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Phase 2

Recruiting

Conditions: Epilepsies, Partial

Interventions: Drug: Cenobamate

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 100

Registration Number: NCT06590896

Locations: 🇯🇵
Ehime University Hospital, Ehime, Japan
🇯🇵
Department of Neurology and Stroke Center, Southern Tohoku Clinic., Fukushima, Japan
🇯🇵
Hiroshima University Hospital, Hiroshima, Japan

and more 26 locations

ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.

Phase 3

Recruiting

Conditions: Epilepsy, Generalized

Interventions: Drug: Cenobamate

First Posted Date: 2024-08-30

Last Posted Date: 2024-08-30

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 12

Registration Number: NCT06579573

Locations: 🇯🇵
Aichi Medical University Hospital, Aichi, Japan
🇯🇵
Hospital of the University of Occupational and Environmental Health, Japan, Fukuoka, Japan
🇯🇵
Hokkaido University Hospital, Hokkaido, Japan

and more 22 locations

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer
Hormone Receptor-positive Breast Cancer
HER2-negative Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: ONO-4578
Drug: letrozole
Drug: abemaciclib
Drug: Palbociclib

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 46

Registration Number: NCT06570031

Locations: 🇯🇵
Saitama Cancer Center, Ina, Saitama, Japan
🇯🇵
Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

and more 10 locations

A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: ONO-4538HSC

First Posted Date: 2024-08-12

Last Posted Date: 2024-12-09

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 31

Registration Number: NCT06548217

Locations: 🇯🇵
Tohoku University Hospital, Sendai-shi, Miyagi, Japan
🇯🇵
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan
🇯🇵
Kindai University Hospital, Osakasayama-shi, Osaka, Japan

and more 4 locations

Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: ONO-4578
Drug: ONO-4538
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Calcium Levofolinate Hydrateb
Drug: Bevacizumab

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 40

Registration Number: NCT06547385

Locations: 🇯🇵
Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan
🇯🇵
Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi, Osaka, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

and more 6 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy